Standardized sTudy With Almotriptan in eaRly Treatment of Migraine

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

NCT05518123 ·Status: COMPLETED ·Phase: PHASE4

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

NCT03939312 ·Status: COMPLETED ·Phase: PHASE3

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

NCT00792103 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

NCT03700320 ·Status: COMPLETED ·Phase: PHASE3

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

NCT04686136 ·Status: COMPLETED ·Phase: PHASE3

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

NCT03777059 ·Status: COMPLETED ·Phase: PHASE3

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505 ·Status: RECRUITING ·Phase: PHASE3

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

NCT03238781 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394 ·Status: RECRUITING ·Phase: PHASE3

Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study

NCT01859481 ·Status: COMPLETED ·Phase: PHASE3

The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain

NCT00212823 ·Status: COMPLETED ·Phase: PHASE4

A Multicenter Assessment of ALD403 in Chronic Migraine

NCT02275117 ·Status: COMPLETED ·Phase: PHASE2

BI 44370 TA in Acute Migraine Attack

NCT00751803 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

NCT02974153 ·Status: COMPLETED ·Phase: PHASE3

Study With Amitriptylin to Evaluate the Efficacy of Melatonin in Treatment of Migraine

NCT01357031 ·Status: COMPLETED ·Phase: PHASE3

Rizatriptan 10 MG RPD in the Treatment of Acute Migraine

NCT01057160 ·Status: COMPLETED ·Phase: PHASE4

A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers

NCT03708744 ·Status: COMPLETED ·Phase: PHASE1

Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine

NCT00210496 ·Status: COMPLETED ·Phase: PHASE4

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT05164172 ·Status: RECRUITING ·Phase: PHASE3

A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents

NCT00210483 ·Status: COMPLETED ·Phase: PHASE3

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

NCT02559895 ·Status: COMPLETED ·Phase: PHASE3

Study of Treatment Used for Migraine Headaches (MK-0974-076)

NCT01421277 ·Status: TERMINATED

Prediction of Migraine Prevention Efficacy Based on Individual's Pain Modulation

NCT02101892 ·Status: COMPLETED ·Phase: NA

Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

NCT05509400 ·Status: COMPLETED ·Phase: PHASE4

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

NCT02848326 ·Status: COMPLETED ·Phase: PHASE2/PHASE3